939972-38-0

Upstream product

• 13331-23-2 fur-2-ylboronic acid 
• 453-17-8 D-Glyceraldehyde 
• 255050-48-7 3-cyano-naphthalene-1-carbonyl chloride 
• 255050-50-1 N-[2-(S)-(3,4-dichlorophenyl)-4-oxobutyl]-N-methyl-3-cyano-1-naphthamide 
• 160707-17-5 (S)-N-[2-(3,4-dichlorophenyl)-4-hydroxybutyl]-N-methylamine 
• 3839-18-7 3-cyano-1-naphthoic acid 
• 939972-59-5 3-cyano-naphthalene-1-carboxylic acid [(2S)-2-(3,4-dichloro-phenyl)-4-methylsulfonyl-butyl]-methyl-amide 
• 939972-62-0 4-((1R,2S)-1-furan-2-yl-2,3-dihydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 255050-49-8 3-cyano-naphthalene-1-carboxylic acid [(2S)-(3,4-dichloro-phenyl)-4-hydroxy-butyl]-methyl-amide 

Relevant academic research and scientific papers

NK1 and NK2-antagonists and compositions and methods of using the same

3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I [image] which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment a

NOVEL NK1 AND NK2 ANTAGONISTS

The present invention relates to novel 3-cyano-naphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors. The present invention is further directed to pharmaceutical compositions c